GRI BIO Files Proxy Statement Supplement

TL;DR

GRI BIO dropped more proxy docs, check 'em before the shareholder meeting.

AI Summary

GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed a Definitive Additional Materials (DEFA14A) document on August 16, 2024. This filing supplements the proxy statement for their annual meeting of stockholders. The company, incorporated in Delaware with its principal office in La Jolla, CA, operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing provides additional materials related to GRI BIO's annual meeting, which is crucial for shareholders to understand before voting on company matters.

Risk Assessment

Risk Level: low — This is a routine filing of additional proxy materials, not indicating any immediate financial or operational risk.

Key Players & Entities

• GRI BIO, Inc. (company) — Registrant
• Vallon Pharmaceuticals, Inc. (company) — Former company name
• 20240816 (date) — Filing date
• La Jolla, CA (location) — Business address

FAQ

Key Financial Figures

• $8,000 — l pay Campaign Management, LLC a fee of $8,000, plus reasonable expenses. Campaign Man

Filing Documents

• a2024proxyadditionalmateri.htm (DEFA14A) — 15KB
• 0001824293-24-000109.txt ( ) — 16KB

From the Filing

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 GRI BIO, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box) No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 SUPPLEMENT TO THE PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS OF GRI BIO, INC. TO BE HELD ON AUGUST 23, 2024 This supplement, dated August 16, 2024, amends and supplements the Proxy Statement of GRI Bio, Inc. ("we" or "GRI"), dated August 2, 2024 (the "Proxy Statement"), relating to the 2024 Annual Meeting of Stockholders (the "Annual Meeting"), with the following information. Appointment of Proxy Solicitor We have hired Campaign Management, LLC to solicit proxies with respect to the Annual Meeting. We will pay Campaign Management, LLC a fee of $8,000, plus reasonable expenses. Campaign Management, LLC will, among other things, provide advice regarding proxy solicitation issues and solicit proxies from our stockholders on our behalf in connection with the Annual Meeting. Important Information GRI has filed a definitive Proxy Statement with the Securities and Exchange Commission and has furnished to its stockholders a Proxy Statement in connection with the solicitation of proxies for the Annual Meeting. GRI advises its stockholders to read the Proxy Statement relating to the Annual Meeting, as amended and supplemented by this supplement, because it contains important information. Except as described in this supplement, none of the items or information presented in the Proxy Statement is affected by this supplement. This supplement does not provide all of the information that is important to your voting decisions at the Annual Meeting. The Proxy Statement contains other important additional information. We encourage you to carefully read this supplement together with the Proxy Statement. Your vote is important , no matter how many or how few shares you may own. If you have not already done so, please vote TODAY by telephone, via the Internet, or by signing, dating and returning the proxy card or voting instruction card previously mailed to you. If you have already returned your proxy or voting instruction card or voted by telephone or via Internet, you do not need to take any action unless you wish to change your vote.

View Full Filing

View this DEFA14A filing on SEC EDGAR